STOCK TITAN

Point72 (ATRA) holds 6.2% of Atara Biotherapeutics as of May 7, 2026

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Atara Biotherapeutics received a Schedule 13G reporting that Point72-affiliated entities beneficially own 526,682 shares of Common Stock, representing 6.2% of the class as of May 7, 2026. The filing states Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen share voting and dispositive power over these shares through Point72 Associates under a joint filing agreement. The reporting persons own no shares directly and the disclosure notes Point72 Associates has the right to receive dividends or sale proceeds for the reported position.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 526,682 shares as of May 7, 2026
Percent of class 6.2% percent of common stock as reported in Item 4
Reporting date May 7, 2026 ownership and voting/dispositive powers stated as of this date
Schedule 13G regulatory
"This statement is filed by: (i) Point72 Asset Management... (Schedule 13G)"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
beneficially owned financial
"Amount beneficially owned: The information required by Item 4(a) is set forth..."
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared dispositive power financial
"Shared Dispositive Power 526,682.00"
Joint Filing Agreement legal
"have entered into a Joint Filing Agreement, a copy of which is filed with this as Exhibit 99.1"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





046513206

(CUSIP Number)
05/07/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:05/08/2026
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:05/08/2026
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:05/08/2026
Exhibit Information

Exhibit 99.1: Joint Filing Agreement

FAQ

What stake does Point72 report in Atara Biotherapeutics (ATRA)?

Point72 reports beneficial ownership of 526,682 shares, or 6.2% of Atara's common stock. That figure is reported as of May 7, 2026 and appears in Row 9 of the cover page and Item 4 of the filing.

Which Point72 entities filed the Schedule 13G for ATRA?

Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen filed jointly. The filing cites a Joint Filing Agreement and notes Cubist Systematic Strategies, LLC acts as a relying sub-adviser for a portion of the shares.

Do the reporting persons directly own the reported Atara shares?

No — the filing states they directly own no shares. Investment and voting power is exercised via Point72 Associates under an investment management agreement, per Item 4 of the filing.

Who has the right to dividends or sale proceeds for the reported shares?

Point72 Associates has the right to receive dividends or proceeds for the reported shares. Item 6 confirms that this right relates to more than 5% of the class and need not list underlying shareholders.